Neurodegenerative disease and obesity: What is the role of weight loss and bariatric interventions?

Metabolic Brain Disease

Volumn 28, Issue 3, 2013, Pages 341-353

  Ashrafian, Hutan ^a   Harling, Leanne ^a   Darzi, Ara ^a   Athanasiou, Thanos ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Bariatric surgery; Neurodegenerative disease; Obesity; Parkinson's disease; Weight loss

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLESTEROL ACYLTRANSFERASE; DOPAMINE; GALANIN; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROPEPTIDE; PRESENILIN 1; PRESENILIN 2; SPHINGOLIPID;

ALZHEIMER DISEASE; ANTIDIABETIC ACTIVITY; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BRAIN FUNCTION; CALORIC RESTRICTION; CELL STRESS; CHOLESTEROL METABOLISM; DEGENERATIVE DISEASE; DIETARY INTAKE; DISEASE COURSE; DNA REPAIR; DOPAMINERGIC NERVE CELL; FOOD INTAKE; GENE EXPRESSION PROFILING; GENE MUTATION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONAL THERAPY; HUMAN; METABOLIC SYNDROME X; NERVE CELL PLASTICITY; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PARKINSON DISEASE; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; RECEPTOR UPREGULATION; REVIEW; SLEEVE GASTRECTOMY; STOMACH BYPASS; WEIGHT REDUCTION;

EID: 84883306729     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-013-9412-4     Document Type: Review

References (148)

1. Aasheim ET, Elshorbagy AK, My Diep L, Sovik TT, Mala T, Valdivia-Garcia M, Olbers T, Bohmer T, Birkeland KI, Refsum H (2011) Effect of bariatric surgery on sulphur amino acids and glutamate. Br J Nutr 106(3):432-440
2. Abbott A (2011) Dementia: a problem for our age. Nature 475(7355):S2-S4
3. Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, Tanner CM, Curb JD, Blanchette PL, Popper JS, Petrovitch H (2002) Midlife adiposity and the future risk of Parkinson's disease. Neurology 59(7):1051-1057
4. Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G (2012) Can Alzheimer disease be a form of type 3 diabetes? Rejuvenation Res 15(2):217-221
5. Adlard PA, Perreau VM, Pop V, Cotman CW (2005) Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 25(17):4217-4221 (Pubitemid 40628765)
6. Ashrafian H (2011) Bariatric surgery: can we afford to do it or deny doing it? Frontline Gastroenterol 2:82-89
7. Ashrafian H, le Roux CW (2009) Metabolic surgery and gut hormones - a review of bariatric entero-humoral modulation. Physiol Behav 97(5):620-631
8. Ashrafian H, le Roux CW, Darzi A, Athanasiou T (2008) Effects of bariatric surgery on cardiovascular function. Circulation 118(20):2091-2102
9. Ashrafian H, Athanasiou T, Li JV, Bueter M, Ahmed K, Nagpal K, Holmes E, Darzi A, Bloom SR (2010a) Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes Rev 12(5):e257-272
10. Ashrafian H, Bueter M, Ahmed K, Suliman A, Bloom SR, Darzi A, Athanasiou T (2010b) Metabolic surgery: an evolution through bariatric animal models. Obes Rev 11(12):907-920
11. Ashrafian H, Darzi A, Athanasiou T (2010c) Autobionics: a new paradigm in regenerative medicine and surgery. Regen Med 5(2):279-288
12. Ashrafian H, Ahmed K, Rowland SP, Patel VM, Gooderham NJ, Holmes E, Darzi A, Athanasiou T (2011a) Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer 117(9):1788-1799
13. Ashrafian H, le Roux CW, Rowland SP, Ali M, Cummin AR, Darzi A, Athanasiou T (2011b) Metabolic surgery and obstructive sleep apnoea: the protective effects of bariatric procedures. Thorax 67(5):442-449
14. Atti AR, Palmer K, Volpato S, Winblad B, De Ronchi D, Fratiglioni L (2008) Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc 56(1):111-116
15. Bakulski KM, Rozek LS, Dolinoy DC, Paulson HL, Hu H (2012) Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. CurrAlzheimer research 9(5):563-573
16. Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA (2001) Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 16(5):830-837 (Pubitemid 36041184)
17. Bhattacharyya R, Kovacs DM (2010) ACAT inhibition and amyloid beta reduction. Biochim Biophys Acta 1801(8):960-965
18. Bihaqi SW, Schumacher A, Maloney B, Lahiri DK, Zawia NH (2012) Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm. Curr Alzheimer research 9(5):574-588
19. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3(3):186-191 (Pubitemid 46825511)
20. Brozinick JT, Hawkins E, Hoang Bui H, Kuo MS, Tan B, Kievit P, Grove K (2012) Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet. Int J Obes. doi: 10.1038/ijo.2012.191
21. Bruce-Keller AJ, Umberger G, McFall R, Mattson MP (1999) Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann Neurol 45(1):8-15 (Pubitemid 29036426)
22. Buxbaum JD, Geoghagen NS, Friedhoff LT (2001) Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alzheimers Dis 3(2):221-229 (Pubitemid 32566521)
23. Chen D, Steele AD, Hutter G, Bruno J, Govindarajan A, Easlon E, Lin SJ, Aguzzi A, Lindquist S, Guarente L (2008) The role of calorie restriction and SIRT1 in prion-mediated neurodegeneration. Exp Gerontol 43(12):1086-1093
24. Chen JQ, Brown TR, Russo J (2009) Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta 1793(7):1128-1143
25. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55(11):1449-1455 (Pubitemid 28525506)
26. Cohn-Hokke PE, Elting MW, Pijnenburg YA, van Swieten JC (2012) Genetics of dementia: update and guidelines for the clinician. Am J Med Genet Part B, Neuropsychiatr Genet: Off Publ Int Soc Psychiatr Genet 159B(6):628-643
27. Contestabile A (2009) Benefits of caloric restriction on brain aging and related pathological States: understanding mechanisms to devise novel therapies. Curr Med Chem 16(3):350-361
28. Counts SE, Perez SE, Ginsberg SD, Mufson EJ (2010) Neuroprotective role for galanin in Alzheimer's disease. EXS 102:143-162
29. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3(3):169-178 (Pubitemid 38229951)
30. D'Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, Rossi F, Paolisso G (2010) Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 45(3):202-207
31. Deweerdt S (2011) Prevention: activity is the best medicine. Nature 475(7355):S16-S17
32. Di Paolo G, Kim TW (2011) Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 12(5):284-296
33. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5):384-386 (Pubitemid 46184217)
34. Duan W, Mattson MP (1999) Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J Neurosci Res 57(2):195-206 (Pubitemid 29300322)
35. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 80(1):101-110 (Pubitemid 34614582)
36. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM, Wojcicki TR, Mailey E, Vieira VJ, Martin SA, Pence BD, Woods JA, McAuley E, Kramer AF (2011) Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A 108(7):3017-3022
37. Farias MM, Cuevas AM, Rodriguez F (2011) Set-point theory and obesity. Metab Syndr Relat Disord 9(2):85-89
38. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100(7):4162-4167 (Pubitemid 36418174)
39. Feart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues JF, Scarmeas N, Barberger-Gateau P (2009) Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA 302(6):638-648
40. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74(12):956-964
41. Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A (2011) Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 6(12):e28032
42. Gahete MD, Rubio A, Cordoba-Chacon J, Gracia-Navarro F, Kineman RD, Avila J, Luque RM, Castano JP (2010) Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis 22(3):819-828
43. Gahete MD, Cordoba-Chacon J, Kineman RD, Luque RM, Castano JP (2011) Role of ghrelin system in neuroprotection and cognitive functions: implications in Alzheimer's disease. Peptides 32(11):2225-2228
44. Gamba P, Testa G, Sottero B, Gargiulo S, Poli G, Leonarduzzi G (2012) The link between altered cholesterol metabolism and Alzheimer's disease. Ann N Y Acad Sci 1259:54-64
45. Gao H, Wang X, Zhang Z, Yang Y, Yang J, Li X, Ning G (2007) GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine 32(1):90-95 (Pubitemid 350242552)
46. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63(2):168-174 (Pubitemid 43213878)
47. Gault VA, Holscher C (2008) GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 587(1-3):112-117
48. Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Tornell J, Westermark P, Sundler F, Ahren B, Betsholtz C (1998) Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 250(2):271-277 (Pubitemid 28463867)
49. Gilbey SG, Stephenson J, O'Halloran DJ, Burrin JM, Bloom SR (1989) High-dose porcine galanin infusion and effect on intravenous glucose tolerance in humans. Diabetes 38(9):1114-1116 (Pubitemid 19250396)
50. Global burden of neurological disorders: estimates and projections (2006). In: Neurological disorders: Public health challenges (http://www.who.int/mental-health/neurology/neurodiso/en/index.html). World Health Organization, Geneva, Chapter 2, p 36
51. Gustafson D (2006) Adiposity indices and dementia. Lancet Neurol 5(8):713-720 (Pubitemid 44062421)
52. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163(13):1524-1528 (Pubitemid 36835095)
53. Hao Z, Wu B, Wang D, Liu M (2011) Association between metabolic syndrome and cognitive decline: a systematic review of prospective population-based studies. Acta Neuropsychiatr 23:69-74
54. Harkavyi A, Whitton PS (2010) Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 159(3):495-501
55. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 5:19 (Pubitemid 351858930)
56. Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G (1996) Diet and Parkinson's disease. II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47(3):644-650
57. Hendrie HC, Ogunniyi A, Hall KS, Baiyewu O, Unverzagt FW, Gureje O, Gao S, Evans RM, Ogunseyinde AO, Adeyinka AO, Musick B, Hui SL (2001) Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 285(6):739-747 (Pubitemid 32167232)
58. Hock C, Heese K, Hulette C, Rosenberg C, Otten U (2000) Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57(6):846-851 (Pubitemid 30397187)
59. Holscher C (2012) Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection. CNS Drugs 26(10):871-882
60. Holst JJ, Burcelin R, Nathanson E (2011) Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 27(3):547-558
61. Hoppener JW, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JH, Vroom TM, Ahren B, Lips CJ (1999) Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42(4):427-434 (Pubitemid 29148401)
62. Hoppener JW, Ahren B, Lips CJ (2000) Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343(6):411-419 (Pubitemid 30626125)
63. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA (2000) Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 166(1):127-135
64. Ittner LM, Gotz J (2011) Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12(2):65-72
65. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53(2):474-481 (Pubitemid 38174565)
66. Jazet IM, de Groot GH, Tuijnebreyer WE, Fogteloo AJ, Vandenbroucke JP, Meinders AE (2007) Cardiovascular risk factors after bariatric surgery: do patients gain more than expected from their substantial weight loss? Eur J Intern Med 18(1):39-43 (Pubitemid 46072731)
67. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356(9242):1627-1631
68. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL (1999) Adult nutrient intake as a risk factor for Parkinson's disease. Int J Epidemiol 28(6):1102-1109 (Pubitemid 30021310)
69. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S (2012) The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 60(10):875-881
70. Jyvakorpi SK, Puranen T, Pitkala KH, Suominen MH (2012) Nutritional treatment of aged individuals with Alzheimer disease living at home with their spouses: study protocol for a randomized controlled trial. Trials 13:66
71. Katsuki H, Michinaga S (2012) Anti-Parkinson drugs and orexin neurons. Vitam Horm 89:279-290
72. Kim Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, Nakaya Y (2009) Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 390(3):613-618
73. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26(13):3169-3179 (Pubitemid 47057498)
74. Kim S, Moon M, Park S (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol 202(3):431-439
75. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322(7300):1447-1451 (Pubitemid 32575406)
76. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20(18):6920-6926
77. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, Haughey N, Lee J, Evans M, Mattson MP (2002) Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22(5):1752-1762 (Pubitemid 35386293)
78. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Buttner T, Woitalla D, Muller T (1998) Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 40(4):225-227 (Pubitemid 28526247)
79. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120(5):701-713 (Pubitemid 40343081)
80. Lee J, Duan W, Long JM, Ingram DK, Mattson MP (2000) Dietary restriction increases the number of newly generated neural cells, and induces BDNF expression, in the dentate gyrus of rats. J Mol Neurosci 15(2):99-108 (Pubitemid 32108679)
81. Lee J, Seroogy KB, Mattson MP (2002) Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice. J Neurochem 80(3):539-547 (Pubitemid 36383037)
82. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145(4):301-308 (Pubitemid 27082028)
83. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19(4):1205-1219
84. Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, Bloom SR, Darzi A, Athanasiou T, Marchesi JR, Nicholson JK, Holmes E (2011a) Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 60(9):1214-1223
85. Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ (2011b) AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 33(7):1400-1410
86. Liu L, Martin R, Chan C (2013) Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases. Neurobiol Aging 34(2):540-550
87. Livhits M, Mercado C, Yermilov I, Parikh JA, Dutson E, Mehran A, Ko CY, Gibbons MM (2010) Exercise following bariatric surgery: systematic review. Obes Surg 20(5):657-665
88. Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R (1996) Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol 39(1):89-94 (Pubitemid 26052221)
89. Luchsinger JA, Tang MX, Shea S, Mayeux R (2002) Caloric intake and the risk of Alzheimer disease. Arch Neurol 59(8):1258-1263 (Pubitemid 34856378)
90. Mattson MP (2003) Will caloric restriction and folate protect against AD and PD? Neurology 60(4):690-695 (Pubitemid 36246090)
91. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S (1999) Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci 893:154-175 (Pubitemid 30038074)
92. Mattson MP, Duan W, Guo Z (2003) Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. J Neurochem 84(3):417-431 (Pubitemid 36182240)
93. McCue MD (2010) Starvation physiology: reviewing the different strategies animals use to survive a common challenge. Comp Biochem Physiol Part A, Mol & integr Physiol 156(1):1-18
94. McIntyre RS, Powell AM, Kaidanovich-Beilin O, Soczynska JK, Alsuwaidan M, Woldeyohannes HO, Kim AS, Gallaugher LA (2012) The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res 237C:164-171
95. Milionis HJ, Florentin M, Giannopoulos S (2008) Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis? CNS spectrums 13(7):606-613
96. Mitsutake S, Igarashi Y (2013) Sphingolipids in lipid microdomains and obesity. Vitam Horm 91:271-284
97. Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR (1996) Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake. Neurology 46(5):1270-1274 (Pubitemid 26159285)
98. Mosselman S, Hoppener JW, Zandberg J, van Mansfeld AD, Geurts van Kessel AH, Lips CJ, Jansz HS (1988) Islet amyloid polypeptide: identification and chromosomal localization of the human gene. FEBS Lett 239(2):227-232 (Pubitemid 18263452)
99. Mutch DM, Fuhrmann JC, Rein D, Wiemer JC, Bouillot JL, Poitou C, Clement K (2009) Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS One 4(11):e7905
100. Muzumdar RH, Huffman DM, Atzmon G, Buettner C, Cobb LJ, Fishman S, Budagov T, Cui L, Einstein FH, Poduval A, Hwang D, Barzilai N, Cohen P (2009) Humanin: a novel central regulator of peripheral insulin action. PLoS One 4(7):e6334
101. Obesity and overweight - Fact Sheet N 311 Updated March 2011 (http://www.who.int/mediacentre/factsheets/fs311/en/index.html) World Health Organization, Geneva
102. Opie EL (1901) The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islands of Langerhans. J Exp Med 5:527-540
103. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53(9):1937-1942
104. Patil S, Melrose J, Chan C (2007) Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. Eur J Neurosci 26(8):2131-2141 (Pubitemid 47620475)
105. Perl DP, Olanow CW, Calne D (1998) Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol 44(3 Suppl 1):S19-S31
106. Perry TA, Greig NH (2004) A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 5(6):565-571 (Pubitemid 39004431)
107. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302(3):881-888 (Pubitemid 34920207)
108. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH (2003) Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72(5):603-612 (Pubitemid 36578646)
109. Plunet WT, Streijger F, Lam CK, Lee JH, Liu J, Tetzlaff W (2008) Dietary restriction started after spinal cord injury improves functional recovery. Exp Neurol 213(1):28-35
110. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362(4):329-344
111. Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton PS (2012) Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions. Neuropeptides 46(5):183-193
112. Razay G, Wilcock GK (1994) Hyperinsulinaemia and Alzheimer's disease. Age Ageing 23(5):396-399 (Pubitemid 24292166)
113. Rebeck GW, Kindy M, LaDu MJ (2002) Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis 4(3):145-154 (Pubitemid 35006046)
114. Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27(3):451-458 (Pubitemid 43185331)
115. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6(4):246-254 (Pubitemid 44137951)
116. Rogers BS, Lippa CF (2012) A clinical approach to early-onset inheritable dementia. AJADD 27(3):154-161
117. Russell MB (2010) Genetics of dementia. Acta Neurol Scandinavica Suppl 190:58-61
118. Sandyk R (1993) The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 69(1-4):125-130
119. Sato N, Takeda S, Uchio-Yamada K, Ueda H, Fujisawa T, Rakugi H, Morishita R (2011) Role of insulin signaling in the interaction between alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr Aging Sci 4(2):118-127
120. Saw SM, Yuan JM, Ong CN, Arakawa K, Lee HP, Coetzee GA, Yu MC (2001) Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. Am J Clin Nutr 73(2):232-239 (Pubitemid 32111746)
121. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y (2009) Physical activity, diet, and risk of Alzheimer disease. JAMA 302(6):627-637
122. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346(7):476-483 (Pubitemid 34441738)
123. Session DR, Pearlstone MM, Jewelewicz R, Kelly AC (1994) Estrogens and Parkinson's disease. Med Hypotheses 42(4):280-282 (Pubitemid 24146407)
124. Sharma S, Kaur G (2005) Neuroprotective potential of dietary restriction against kainate-induced excitotoxicity in adult male Wistar rats. Brain Res Bull 67(6):482-491 (Pubitemid 41416743)
125. Sheard JM, Ash S, Silburn PA, Kerr GK (2013) Nutritional status in Parkinson's disease patients undergoing deep brain stimulation surgery: a pilot study. J Nutr, health Aging 17(2):148-151
126. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351(26):2683-2693 (Pubitemid 39665322)
127. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357(8):741-752 (Pubitemid 47295641)
128. Sledzinski T, Goyke E, Smolenski RT, Sledzinski Z, Swierczynski J (2011) Decreased serum betaine concentrations in patients after bariatric surgery. Obes Surg 21(10):1634-1639
129. Sriram K, Benkovic SA, Miller DB, O'Callaghan JP (2002) Obesity exacerbates chemically induced neurodegeneration. Neuroscience 115(4):1335-1346 (Pubitemid 35351719)
130. Steel JH, Gon G, O'Halloran DJ, Jones PM, Yanaihara N, Ishikawa H, Bloom SR, Polak JM (1989) Galanin and vasoactive intestinal polypeptide are colocalised with classical pituitary hormones and show plasticity of expression. Histochemistry 93(2):183-189 (Pubitemid 20001186)
131. Stewart R, Masaki K, Xue QL, Peila R, Petrovitch H, White LR, Launer LJ (2005) A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 62(1):55-60 (Pubitemid 40105036)
132. Stolk RP, Breteler MM, Ott A, Pols HA, Lamberts SW, Grobbee DE, Hofman A (1997) Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care 20(5):792-795 (Pubitemid 27202530)
133. Sutoo D, Akiyama K (2003) Regulation of brain function by exercise. Neurobiol Dis 13(1):1-14 (Pubitemid 36564856)
134. Suzuki K, Katzman R, Korey SR (1965) Chemical studies on Alzheimer's disease. J Neuropathol Exp Neurol 24:211-224
135. Swerdlow RH, Burns JM, Khan SM (2010) The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20(Suppl 2):S265-S279
136. Tangney CC, Kwasny MJ, Li H, Wilson RS, Evans DA, Morris MC (2011) Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr 93(3):601-607
137. van Echten-Deckert G, Walter J (2012) Sphingolipids: critical players in Alzheimer's disease. Progr Lipid Res 51(4):378-393
138. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS (2001) Brain dopamine and obesity. Lancet 357(9253):354-357 (Pubitemid 32128542)
139. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S (2003) Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60(12):1899-1903 (Pubitemid 36736003)
140. Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker LD, Peskind ER, Asthana S, Plymate SR, Frolich L, Craft S (2006) Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol Aging 27(1):38-41 (Pubitemid 41627948)
141. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71(14):1057-1064
142. Wolf SA, Kronenberg G, Lehmann K, Blankenship A, Overall R, Staufenbiel M, Kempermann G (2006) Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease. Biol Psychiatry 60(12):1314-1323 (Pubitemid 44838527)
143. Wolozin B (2004) Cholesterol and the biology of Alzheimer's disease. Neuron 41(1):7-10 (Pubitemid 38068431)
144. Woodard GA, Peraza J, Bravo S, Toplosky L, Hernandez-Boussard T, Morton JM (2010) One year improvements in cardiovascular risk factors: a comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding. Obes Surg 20(5):578-582
145. World Alzheimer Report 2010: The Global Economic Impact of Dementia (2010). Alzheimer's Disease International, London
146. Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, Fratiglioni L (2011) Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 76(18):1568-1574
147. Yu ZF, Mattson MP (1999) Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J Neurosci Res 57(6):830-839 (Pubitemid 29416113)
148. Zhu H, Guo Q, Mattson MP (1999) Dietary restriction protects hippocampal neurons against the death-promoting action of a presenilin-1 mutation. Brain Res 842(1):224-229 (Pubitemid 29447872)